Effect of melphalan 140 mg/m2 vs 200 mg/m2 on toxicities and outcomes in multiple myeloma patients undergoing single autologous stem cell transplantation-a single center experience

Effect of melphalan 140 mg/m2 vs 200 mg/m2 on toxicities and outcomes in multiple myeloma patients undergoing single autologous stem cell transplantation-a single center experience

Although melphalan at a dose of 140 mg/m2 (MEL140) is an acceptable conditioning regimen for autologous stem cell transplantation (ASCT) in multiple myeloma (MM) patients, very few studies compared it to the most commonly used dose of 200 mg/m2 (MEL200). A retrospective review of records of MM patie...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical transplantation 2016-08, Vol.30 (8), p.894-900
Hauptverfasser: Katragadda, Lakshmikanth, McCullough, Lindsay M., Dai, Yunfeng, Hsu, Jack, Byrne, Michael, Hiemenz, John, May, Stratford, Cogle, Christopher R., Norkin, Maxim, Brown, Randy A., Wingard, John R., Chang, Myron, Moreb, Jan S.
Format: Artikel
Sprache:eng
Schlagworte:
autologous stem cell transplantation
melphalan dose
multiple myeloma
outcomes
toxicities
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Although melphalan at a dose of 140 mg/m2 (MEL140) is an acceptable conditioning regimen for autologous stem cell transplantation (ASCT) in multiple myeloma (MM) patients, very few studies compared it to the most commonly used dose of 200 mg/m2 (MEL200). A retrospective review of records of MM patients (2001–2010) identified 33 patients who received MEL140 and 96 patients who received MEL200. As expected, significantly higher percentage of patients in the MEL140 arm were >65 years or had cardiac ejection fraction
ISSN:0902-0063
1399-0012
DOI:10.1111/ctr.12762